ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1595	National Cancer Institute	Html	en	Gastric Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of gastric cancer.	treatment 0.591238 cancer treatment 0.450405 gastric cancer cells 0.441573 Gastric Cancer Treatment 0.444726 NCI-supported cancer 0.4391 stomach 0.735063 cancer cells 0.582767 malignant tumor cells 0.419107 body 0.442061 Cancer Information Service 0.403362 PDQ cancer information 0.496418 specific cancer cells 0.40594 HER2-positive gastric cancer 0.441612 clinical trial search 0.508645 stomach wall 0.679257 treatment clinical trials 0.435225 National Cancer Institute 0.459181 clinical trials 0.857251 nearby lymph nodes 0.422969 cancer information summary 0.459638 clinical trial 0.69582 gastric cancer spreads 0.435883 new treatment 0.430993	gastric cancer 0.961916 recurrent gastric cancer 0.423214 ) layer. 0.427318 stomach disease 0.413534 patients 0.40139 metastatic gastric cancer 0.437702 Stomach pain 0.405557 NCI PDQ cancer 0.415126 cancer clinical trials 0.531962 lymph nodes 0.644979 stage 0.470953 stomach cancer 0.464876 tumor 0.483246 chemoradiation therapy 0.469475 radiation therapy 0.455319 Treatment Editorial Board 0.403905 cancer information summaries 0.401354 stomach discomfort 0.411852 information 0.507295 small intestine 0.476652 subtotal gastrectomy 0.452908 monoclonal antibody 0.404834 General information 0.405606	CLICK HERE
1684	National Cancer Institute	Html	en	Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of Gastrointestinal Stromal Tumors	imatinib response 0.41821 higher-dose imatinib mesylate 0.47787 imatinib therapy. 0.433313 Demetri GD 0.381845 TKI imatinib mesylate 0.494206 KIT receptor tyrosine 0.378346 KIT exon 0.370015 gastrointestinal stromal cell 0.41709 KIT-expressing primary GIST 0.416866 small GIST tumors 0.5328 gastrointestinal stromal tumour 0.414558 patients 0.452898 primary GIST 0.421404 complete gross resection 0.401005 adjuvant imatinib 0.525629 gastrointestinal stromal tumor 0.540132 GIST morphology 0.406777 high-dose imatinib 0.421288 stromal tumor resection 0.405207 tyrosine kinase inhibitor 0.379801 GIST patients 0.413735 et al. 0.374864 GIST resection 0.432449 tyrosine kinase 0.423999	metastatic GIST 0.418294 imatinib resistance 0.431916 gastrointestinal stromal tumors 0.903165 recurrent GIST 0.424604 imatinib mesylate 0.752767 imatinib therapy 0.416737 tyrosine kinase inhibitors 0.389426 imatinib ultimately experience 0.466343 GIST range 0.411206 imatinib-resistant GIST 0.405402 GIST 0.738771 Abstract 0.430607 common mesenchymal tumors 0.369545 Clin Oncol 0.46383 imatinib doses 0.430101 imatinib arm 0.426642 Familial GIST 0.424119 indolent GIST 0.42682 gastrointestinal stromal tumours 0.756245 imatinib era 0.421816 inoperable GIST 0.404394 new GIST cases 0.474154 advanced incurable GIST 0.424115 postoperative adjuvant imatinib 0.452036	CLICK HERE
1691	National Cancer Institute	Html	en	Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®)–Health Professional Version	Calcium, green tea, lycopene, pomegranate, selenium, soy and vitamin E have been studied for prostate cancer prevention or treatment. Read about laboratory and human studies on various prostate supplements in this expert-reviewed summary.	atypical small acinar 0.591788 dietary lycopene 0.5816 local-stage prostate cancer 0.605358 prostate cancer cell 0.611618 prostate cancer survivors 0.597981 total prostate cancer 0.586726 occult prostate cancer 0.591218 lycopene serum concentration 0.581941 lycopene intake 0.604495 prostate cancer cells. 0.594787 serum lycopene 0.591044 hormone-refractory prostate cancer 0.585389 metastatic prostate cancer 0.596215 cancer prostate cells 0.587339 prostate cancer incidence 0.586787 prostate cancer cells 0.74273 prostate cancer risk 0.675977 prostate cancer patients 0.695715 serum lycopene concentrations 0.582255 prostate cancer aggressiveness 0.585035 prostate cancer progressi 0.584763 lycopene 0.683385 end-of-study prostate lycopene 0.623399 Prostate Cancer Prevention 0.597202 serum psa levels 0.589012	human prostate cancer 0.61272 plasma lycopene levels 0.594142 study 0.645275 androgen-independent prostate cancer 0.585034 prostate cancer development 0.59941 nonmetastatic prostate cancer 0.584711 -resistant prostate cancer 0.587482 high-grade prostate cancer 0.596056 Prostate CAncer Therapy 0.605352 prostate cancer mortality 0.5969 prostate cancer biomarkers 0.590502 prostate cancer cases 0.586568 prostate lycopene concentration 0.627986 green tea 0.644093 prostate cancer patients. 0.585445 lycopene blood levels 0.586499 prostate cancer 0.954937 prostate cancer. 0.620441 aggressive prostate cancer 0.587452 prostate cancer risk. 0.60813 prostate cancer progression 0.591862 prostate lycopene concentrations 0.629097 lycopene levels 0.595352 small acinar proliferation 0.592927	CLICK HERE
1753	National Cancer Institute	Html	en	Hormone Therapy for Breast Cancer	A fact sheet that describes types of hormone therapy, its role in preventing and treating breast cancer, and possible side effects.	Surgical Adjuvant Breast 0.492707 estrogen 0.502159 primary breast cancer 0.489122 early-stage ER-positive breast 0.480551 aromatase inhibitors anastrozole 0.480936 ER-positive early-stage breast 0.480383 aromatase inhibitors 0.525562 breast cancer subtypes 0.491642 metastatic ER-positive breast 0.481109 early-stage breast cancer 0.616245 tamoxifen 0.550216 breast cancer hormone 0.522198 ER-positive breast cancer 0.553345 breast cancer prevention 0.522495 breast cancer patients 0.511592 postmenopausal breast cancer 0.509489 new breast cancer 0.500245 adjuvant hormone therapy 0.504935 estrogen receptors 0.483294 HR-positive breast cancer 0.521679 hormone receptor-positive breast 0.501962 metastatic breast cancer 0.52726 invasive breast cancer 0.511911 early breast cancer 0.587772	breast cancer cells 0.575964 breast cancer recurrence 0.50934 breast cancers 0.514423 ER-positive breast cancers 0.488424 premenopausal women 0.499525 National Cancer Institute 0.500748 IBIS-I breast cancer 0.488534 hormone therapy 0.718328 hormone-sensitive breast cancer 0.587411 breast tumors 0.505842 postmenopausal women 0.702436 breast cancer risk 0.498557 International Breast Cancer 0.496186 Letrozole Breast Cancer 0.491109 estrogen receptor 0.488845 advanced hormone-sensitive breast 0.480069 receptor–positive breast cancer 0.52072 breast cancer 0.988243 Breast Cancer Trialists 0.51995 adjuvant tamoxifen 0.489054 tamoxifen treatment 0.48115 hormone receptor–positive breast 0.534822 et al 0.566786 advanced breast cancer 0.554835	CLICK HERE
1762	National Cancer Institute	Html	en	Access to Investigational Drugs	A fact sheet that defines investigational drugs (drugs under study but not yet FDA approved) and describes ways one might get access to these treatments.	NCI-designated cancer centers 0.38027 specific drug 0.365425 following criteria 0.380266 NCI program 0.360621 NCI’s Cancer 0.393319 case-by-case basis 0.385443 specific investigational drug 0.531382 FDA approval process 0.46336 NCI’s role 0.358363 TRC protocol 0.386712 Biologics License Application 0.383962 Institutional Review Board 0.372082 special exception programs 0.401115 investigational agent 0.482556 clinical trials 0.558265 specific criteria 0.382975 U.S. Food 0.350319 special exception mechanism 0.383615 clinical trial 0.636376 patients 0.498827 Special Exception/Compassionate Exemption 0.383931 access protocol 0.441767 drug development 0.379672 study sponsor 0.351362 Investigational New Drug 0.563996	FDA approval 0.502957 New Drug Application 0.4108 wide geographic availability 0.374872 NCI 0.425588 expanded access protocols 0.412645 IND 0.351277 investigational drug 0.866441 sponsor 0.450913 treatment 0.39466 access 0.446945 new drugs 0.396554 Drug Administration 0.379954 Cancer Information Service 0.448715 special exception 0.541023 compassionate exception 0.351227 investigational drugs 0.95169 patient 0.385651 appropriate reviewing division 0.371824 drug company 0.56293 expanded access protocol 0.400476 health insurance company 0.376702 CIS information specialists 0.382598 clinical trials database 0.391459 Treatment Referral Center 0.38112	CLICK HERE
1906	National Cancer Institute	Html	es	Tratamiento de la leucemia linfocítica crónica (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de la leucemia linfocítica crónica.	origen judío ruso 0.422021 siguientes procedimientos 0.424569 células madre 0.989491 estadio iv 0.439551 siguientes aspectos 0.415966 proteína llamada bcl2 0.417559 leucemia linfoblástica aguda 0.524325 hueso compacto 0.45509 neoplasias mieloides 0.413049 rayos x 0.41087 Chronic Lymphocytic Leukemia 0.453986 estadios i 0.422864 enlace drugs approved 0.452281 célula madre mieloide 0.477075 células mieloides 0.465027 células t 0.445647 células anormales.ampliar aspiración 0.467907 National Cancer Institute 0.4112 sexo masculino 0.412514 Instituto Nacional 0.418791	LLC mejora 0.413093 célula madre linfoide 0.435741 PDQ Tratamiento 0.432911 exploración tep 0.412807 siguientes problemas 0.415002 presente sección 0.408632 leucemia mielógena 0.445228 explorador tep 0.413444 tirosina cinasa 0.45926 Physician Data Query 0.439508 estadio iii 0.439039 linfocitos t 0.431485 laboratorio piezas 0.414056 Antecedentes familiares 0.410684 leucemia mieloide aguda 0.50943 célula madre 0.588281 células sanguíneas maduras 0.551856 gen igvh 0.469992 siguientes sumarios 0.426268 siguientes pruebas 0.415779	CLICK HERE
2107	National Cancer Institute	Html	es	Prevención del cáncer de endometrio (PDQ®)–Versión para pacientes	Sumario de información revisada por expertos sobre factores que pueden influir en el riesgo de presentar cáncer de endometrio y sobre las investigaciones dirigidas a prevenir esta enfermedad.	complementos alimenticios 0.438977 siguientes factores 0.924317 voluntarios sanos 0.439137 Physician Data Query 0.577787 Estados Unidos 0.455812 suficiente ejercicio 0.459491 siguientes enfermedades 0.450904 prevención revisa 0.444255 PDQ Prevención 0.479432	mujer presente cáncer 0.809715 siguientes formas 0.459762 National Cancer Institute 0.445519 efecto protector 0.44325 alta concentración 0.443843 siguientes riesgos 0.434346 edad promedio 0.45542 siguientes sumarios 0.513663 Instituto Nacional 0.483875	CLICK HERE
3598	National Cancer Institute	Html	en	Childhood Cancer Survivor Study: An Overview	Health problems that develop years later as a result of a cancer treatment are known as late effects. The Childhood Cancer Survivor Study (CCSS) was started in 1994 to better understand these late effects.	Cancer Survivor Study 0.651761 Clinical Oncology 0.430017 childhood cancer 0.933179	journal article 0.545579 childhood cancer survivor 0.797555	CLICK HERE
14596	National Cancer Institute	Html	en	What Is Cancer?	Explanations about what cancer is, how cancer cells differ from normal cells, and genetic changes that cause cancer to grow and spread.	benign brain tumors 0.40676 star-shaped brain cells 0.473891 human cells 0.482443 nearby normal cells 0.498609 squamous cells 0.495031 body’s cells 0.493774 tumor suppressor genes 0.441927 white blood cells 0.5174 malignant tumors 0.410135 Reed-Sternberg cells 0.446673 abnormal plasma cells 0.47073 tissues 0.391204 epithelial cell types 0.372838 extra cells 0.532701 blood vessels 0.389179 nerve cells 0.450383 solid tumors 0.421449 DNA repair genes 0.397134 Metastatic tumors 0.385874 carcinoid tumors 0.394635 metastatic breast cancer 0.390046 cancers 0.429846 immune system cells 0.472603 myeloma cells 0.447313 soft tissue sarcoma 0.382156	neuroendocrine tumors 0.396625 different cells 0.465518 abnormal cells 0.497795 metastatic cancer cells 0.542261 cancer cells 0.711115 normal blood cells 0.520987 unneeded cells 0.469669 new cells 0.509463 squamous cell 0.373428 normal cells 0.564574 types 0.419663 epithelial cells 0.524359 Cancerous tumors 0.382835 genetic changes 0.400724 tumors 0.551639 germ cell tumors 0.421823 cells 0.91549 new tumors 0.381387 benign tumors 0.426682 damaged cells 0.483579 cells function 0.467145 cancer 0.716841 leukemia cells 0.447258 spinal cord tumors 0.44102	CLICK HERE
16146	National Cancer Institute	Html	es	Virus de la enfermedad de Newcastle (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso del virus de la enfermedad de Newcastle (VEN) como tratamiento para las personas con cáncer.	tumor cell immunogenicity 0.407212 Cancer Res Clin 0.40874 active specific immunotherapy 0.409234 abstract from 0.408151 with newcastle 0.446575 with virus-modified 0.40752 oncolytic virus 0.412098 Reichard KW 0.412175 with virally modified 0.408993 treated postsurgically with 0.409032 Cancer Res 0.456074 Schirrmacher V 0.472403 Csatary LK 0.410713 virus selectively kills 0.408217 Natl Cancer Inst 0.453624 human tumor 0.419154 immunotherapy with 0.411294 Attenuated veterinary virus 0.408258 Ahlert T 0.417009 patients with 0.422834 autologous tumor cells 0.443634 immunotherapy with virally 0.409777 immunization with 0.407432 Lorence RM 0.416992 modified autologous tumor 0.409356	newcastle disease virus 0.990705 virus infeccioso destrucción 0.419778 Lítica Virus 0.418733 virus as 0.414895 tumor cell modification 0.407198 tumor cells 0.594311 virus therapy 0.428512 specific immunotherapy 0.411581 postsurgically with newcastle 0.414603 Cassel WA 0.412481 tumor vaccines 0.414853 Clin Oncol 0.407495 patient with 0.407334 virus mutant with 0.411813 after local newcastle 0.411338 postoperative immunotherapy with 0.409993 malignant melanoma patients 0.409365 with tumor cells 0.411774 renal cell carcinoma 0.40842 malignant melanoma 0.414222 tumor necrosis 0.410434 in vitro 0.430542 virus is reviving 0.408425 active specific 0.412889	CLICK HERE